BI-6C9 is primarily utilized in the field of biomedical research, particularly in studies focused on cancer therapy. It functions as a selective inhibitor targeting specific cellular pathways that are crucial for the survival and proliferation of cancer cells. Researchers employ BI-6C9 to investigate its potential in inducing apoptosis in malignant cells, thereby providing insights into novel therapeutic strategies. Additionally, it is used in preclinical models to evaluate its efficacy and safety profile, contributing to the development of targeted cancer treatments. Its role in modulating key biological processes also makes it a valuable tool for understanding the molecular mechanisms underlying tumor growth and resistance to conventional therapies.